Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 407 participants.

Also called NCT06005597

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 407 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06005597
Main results
  • Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trial Lancet (London, England), 2025-05-17 DOI, PubMed 40347969

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06005597. Randomized; quadruple masking; primary purpose treatment. Start 2024-03-01 (actual); primary completion 2024-09-25 (actual). Results posted on 2025-10-08.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies
Acronym
TANDEM
Condition
Dyslipidemias
Condition
Hypercholesterolemia
Condition
ASCVD
Condition
High Cholesterol
Intervention (Combination product)
Combination Therapy
Intervention (Drug)
Monotherapy obicetrapib
Intervention (Drug)
Monotherapy ezetimibe
Intervention (Other)
Combination Therapy placebo
Intervention (Other)
Obicetrapib Placebo
Intervention (Other)
Ezetimibe Placebo
Lead sponsor
NewAmsterdam Pharma (class: industry)

Record details

Record id
cardio:ct-nct06005597
Content hash
a9f17d3376ce16ab2a6c66714847ff0b868fc9ea76a34e11669f83f15d769bd1